摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,8-dimethyl-2-(2-oxo-2-phenylethyl)-[1,2,4]triazolo[4,3-b]pyridazin-2-ium bromide | 17258-09-2

中文名称
——
中文别名
——
英文名称
6,8-dimethyl-2-(2-oxo-2-phenylethyl)-[1,2,4]triazolo[4,3-b]pyridazin-2-ium bromide
英文别名
6,8-Dimethyl-2-benzoylmethyl-symm.-triazolo<4,3-b>pyridazinium-bromid-(2);2-(6,8-Dimethyl-[1,2,4]triazolo[4,3-b]pyridazin-4-ium-2-yl)-1-phenylethanone;bromide
6,8-dimethyl-2-(2-oxo-2-phenylethyl)-[1,2,4]triazolo[4,3-b]pyridazin-2-ium bromide化学式
CAS
17258-09-2
化学式
Br*C15H15N4O
mdl
——
分子量
347.214
InChiKey
HPTTZKHYWLXVRD-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.48
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    51.9
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    6,8-dimethyl-2-(2-oxo-2-phenylethyl)-[1,2,4]triazolo[4,3-b]pyridazin-2-ium bromideN,N-二异丙基乙胺 、 sodium hydroxide 作用下, 以 乙醇 为溶剂, 反应 32.0h, 生成 ethyl 6,8-dimethylimidazo[1,2-b]pyridazine-3-carboxylate
    参考文献:
    名称:
    [EN] SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
    [FR] IMIDAZO[1,2-B]PYRIDAZINES SUBSTITUÉES, IMIDAZO[1,5-B]PYRIDAZINES SUBSTITUÉES, COMPOSÉS APPARENTÉS ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
    摘要:
    该发明提供了替代咪唑并[1,2-b]吡啶嗪化合物,替代咪唑并[1,5-b]吡啶嗪化合物,相关化合物,含有这些化合物的组合物,医疗工具包,以及使用这些化合物和组合物治疗医疗疾病(例如高雪氏病、帕金森病、Lewy体病、痴呆症或多系统萎缩)的方法,适用于患者。这里描述的示例替代咪唑并[1,2-b]吡啶嗪化合物包括替代咪唑并[1,2-b]吡啶嗪-3-羧酰胺化合物及其变体。
    公开号:
    WO2017192930A1
  • 作为产物:
    参考文献:
    名称:
    选择性,口服活性GPR4拮抗剂的发展对痛觉,炎症和血管生成的调节作用。
    摘要:
    从铅化合物1a开始开发了一种新型的,选择性的,有效的GPR4拮抗剂13。尽管化合物1a在几种疾病模型中显示出有希望的功效,但其与H 3受体以及hERG通道的结合阻止了其进一步发展。因此,进行了针对关键负债的新一轮优化,并导致发现了具有改进特性的化合物13。化合物13在耐受良好的30 mg / kg剂量下,在大鼠抗原诱导的关节炎以及痛觉过敏和血管生成模型中显示出显着的功效。
    DOI:
    10.1021/acs.jmedchem.6b01703
点击查看最新优质反应信息

文献信息

  • [EN] TRANSLOCATOR PROTEIN LIGANDS<br/>[FR] LIGANDS DE LA PROTÉINE DE TRANSLOCATION
    申请人:UNIV SYDNEY
    公开号:WO2009079683A1
    公开(公告)日:2009-07-02
    The present invention relates to compounds and methods for imaging translocator protein (18 kDa) (TSPO) expression in a subject. This invention also relates to compounds and methods for the treatment of neurodegenerative disorders, inflammation or anxiety in a subject.
    本发明涉及用于在受试者中成像转运蛋白(18 kDa)(TSPO)表达的化合物和方法。本发明还涉及用于治疗受试者中的神经退行性疾病、炎症或焦虑的化合物和方法。
  • Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
    申请人:BIAL—R&D Investments, S.A.
    公开号:US11168087B2
    公开(公告)日:2021-11-09
    The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,2-b]pyridazine compounds described herein include substituted imidazo[1,2-b]pyridazine-3-carboxamide compounds and variants thereof.
    本发明提供了取代的咪唑并[1,2-b]哒嗪化合物、取代的咪唑并[1,5-b]哒嗪化合物、相关化合物、含有此类化合物的组合物、医用试剂盒以及使用此类化合物和组合物治疗患者的内科疾病(如戈谢病、帕森病、路易体病、痴呆症或多系统萎缩)的方法。本文所述的示例性取代咪唑并[1,2-b]哒嗪化合物包括取代咪唑并[1,2-b]哒嗪-3-甲酰胺化合物及其变体。
  • SUBSTITUTED IMIDAZO[1,2-b
    申请人:Lysosomal Therapeutics Inc.
    公开号:EP3452481A1
    公开(公告)日:2019-03-13
  • SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b] PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
    申请人:Lysosomal Therapeutics Inc.
    公开号:US20170355702A1
    公开(公告)日:2017-12-14
    The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,2-b]pyridazine compounds described herein include substituted imidazo[1,2-b]pyridazine-3-carboxamide compounds and variants thereof.
  • SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
    申请人:Bial - R&D Investments, S.A.
    公开号:US20220185814A1
    公开(公告)日:2022-06-16
    The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,2-b]pyridazine compounds described herein include substituted imidazo[1,2-b]pyridazine-3-carboxamide compounds and variants thereof.
查看更多